Public Health Impact of Using Biosimilars, Is Automated Follow up Relevant?

Biologic reference drugs and their copies, biosimilars, have a complex structure. Biosimilars need to demonstrate their biosimilarity during development but unpredictable variations can remain, such as micro-heterogeneity. The healthcare community may raise questions regarding the clinical outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Perpoil, Antoine, Grimandi, Gael, Birklé, Stéphane, Simonet, Jean-François, Chiffoleau, Anne, Bocquet, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796345/
https://www.ncbi.nlm.nih.gov/pubmed/33383867
http://dx.doi.org/10.3390/ijerph18010186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796345/
https://www.ncbi.nlm.nih.gov/pubmed/33383867
http://dx.doi.org/10.3390/ijerph18010186

Ejemplares similares